Intersect ENT is a medical company that focuses on producing treatments for ears, nose and throat conditions through innovative research. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. They were formerly known as Sinexus, Inc. but changed their name to Intersect ENT in 2009. They were founded in 2003, and their headquarters are located in Menlo Park, California. They develop a pipeline of steroid releasing implants designed to provide ENT physicians with options to treat patients.